12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

535

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG: Ibodutant 10 mg
DRUG: Placebo

Sponsor

Menarini Group